Diclofenac

證據等級: L5

預測適應症: 10 個

Diclofenac: From Pain & Inflammation to Juvenile Idiopathic Arthritis

One-Sentence Summary

Diclofenac is a well-established NSAID (non-steroidal anti-inflammatory drug) widely used in adults for pain, inflammation, rheumatoid arthritis, and osteoarthritis, acting through dual COX-1/COX-2 inhibition. The TxGNN model generated 10 predicted indications; among them, Juvenile Idiopathic Arthritis (JIA) is the only candidate with meaningful clinical evidence (TxGNN score: 99.25%, rank 9 of 10 predicted). This direction is supported by 2 registered clinical trials and 18 publications, reaching Evidence Level L2, with a recommendation to Proceed with Guardrails.

Note: The TxGNN top-ranked prediction (rank 1) is “hypotrichosis simplex of the scalp” (score: 99.69%), but this and 8 other predictions are classified as L5/Hold due to absence of clinical evidence or mechanistic rationale. This report focuses on JIA as the only actionable finding.

Quick Overview

Item	Content
Original Indication	Pain and inflammation (NSAID; referenced as standard therapy in JIA literature)
Predicted New Indication (Highest Evidence)	Juvenile Idiopathic Arthritis (JIA)
TxGNN Prediction Score	99.25%
Evidence Level	L2
Philippines Market Status	✗ Not Marketed
Number of Registrations	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

The core pathology of JIA involves synovial membrane COX-2 overexpression, leading to prostaglandin E2 (PGE2) accumulation in joint tissue, which drives chronic inflammation, swelling, and pain. Diclofenac is a dual COX-1/COX-2 inhibitor that directly blocks prostaglandin biosynthesis at its root. This is the same mechanism that underpins Diclofenac’s established efficacy in adult inflammatory arthritis—JIA is pharmacologically its pediatric counterpart.

The mechanistic bridge from adult arthritis to JIA is therefore straightforward, not speculative. Multiple clinical studies dating from the 1980s to 1990s directly investigated Diclofenac at weight-based dosing (2 mg/kg/day) in children with juvenile chronic/rheumatoid arthritis, establishing both its pharmacokinetic profile in pediatric patients (including those as young as 2 years) and comparable clinical efficacy to other NSAIDs. A 2007 survey study confirms that Diclofenac was already licensed in some jurisdictions specifically for children over 1 year of age for juvenile rheumatoid arthritis treatment.

Currently, detailed mechanism of action data is not available in this evidence pack (data gap). Based on established pharmacological knowledge, Diclofenac inhibits cyclooxygenase enzymes, reducing prostaglandin synthesis throughout the body. In JIA, where this pathway is central to the autoimmune-driven synovial inflammation, Diclofenac’s mechanism is directly applicable and supported by decades of clinical use across multiple countries.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT00688545	Observational (N/A)	Terminated	275	Multi-center safety registry comparing celecoxib vs. non-selective NSAIDs (including Diclofenac) in JIA patients; collected long-term safety data in real-world clinical practice
NCT05871086	Phase 2/3	Unknown	60	CoQ10 supplementation added to standard JIA therapy; Diclofenac serves as standard background treatment, indirectly confirming its routine use in JIA management

Literature Evidence

PMID	Year	Type	Journal	Key Findings
3052965	1988	Crossover RCT	Clinical and Experimental Rheumatology	Single-blind crossover trial in 28 children with seronegative JCA over 12 weeks; Diclofenac 2 mg/kg/day compared to naproxen and tolmetin; clinical and laboratory outcomes assessed
6361986	1983	Clinical Trial	Scandinavian Journal of Rheumatology	Diclofenac sodium in JRA; pharmacokinetic characterization in children aged 2–7; plasma levels and renal elimination following 25 mg enteric-coated tablet
10756785	1997	Comparative Analysis	Revista Medico-Chirurgicala	100 children with JCA divided into diclofenac, ibuprofen, and aspirin groups; followed over 8 years with clinical and laboratory evaluations at 2, 4, 6 months and 2–3 years
8422565	1993	Review	British Journal of Rheumatology	NSAIDs in pediatric rheumatic diseases; diclofenac, ibuprofen, tolmetin, and naproxen found equal in efficacy and tolerability for joint symptom control
11735667	2001	Safety Review	Paediatric Drugs	Risk-benefit analysis of NSAIDs in children; JIA and Kawasaki disease as key indications; COX inhibition mechanism and pediatric PK/PD profile reviewed
1884567	1991	PK Study	Clinical Pharmacokinetics	Pharmacokinetics of drugs used in juvenile arthritis; NSAIDs including Diclofenac reviewed; disease defined as objective arthritis for ≥6 weeks in children ≤16 years
17474954	2007	Survey	Paediatric Anaesthesia	Survey of UK/Ireland paediatric anaesthetists; confirms Diclofenac is licensed for children over 1 year for juvenile rheumatoid arthritis; highlights off-label use patterns
2235663	1990	Clinical Study	Pediatria Medica e Chirurgica	Open non-comparative study evaluating Diclofenac sodium efficacy in polyarticular JCA; 26 patients aged 2–16 years, disease duration 3 months–14 years
21175420	2010	Review	Critical Reviews in Therapeutic Drug Carrier Systems	NSAIDs microencapsulation for arthritis including JIA; Diclofenac as key drug; covers OA, RA, septic arthritis, JIA, and ankylosing spondylitis
37144854	2023	Case Series	Pediatric Pulmonology	JIA presenting as diffuse alveolar hemorrhage at onset; clinical characterization of a rare JIA manifestation; highlights diagnostic complexity

Philippines Market Information

Diclofenac currently has no registered products with FDA Philippines. No license records are available.

Despite the absence of Philippines registration, Diclofenac is one of the most widely used NSAIDs globally and has existing pediatric use authorization in multiple other jurisdictions. Philippines regulatory filing would be required before any clinical application.

Safety Considerations

Please refer to the package insert for safety information. Safety data (warnings, contraindications, and drug interactions) was not retrievable in this evidence pack and represents a blocking data gap (DG001) that must be resolved before proceeding to a formal safety evaluation.

Key action required: Download and parse the Philippines FDA (or originating country) package insert PDF to extract warnings and contraindications. This is classified as a Blocking severity gap that prevents progression to Safety Stage 1 (S1) assessment.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: Diclofenac’s COX inhibition mechanism directly addresses JIA’s core inflammatory pathway (COX-2/PGE2 overexpression in synovium), and the efficacy in pediatric arthritis has been documented in multiple clinical trials and comparative studies since the 1980s—with at least one country already licensing it specifically for children over 1 year of age for juvenile rheumatoid arthritis. The evidence profile reaches L2, warranting conditional progression subject to safety data retrieval and current standard-of-care alignment.

To proceed, the following is needed:

[Blocking] Retrieve Philippines FDA package insert to extract contraindications and key warnings (DG001)
[High] Obtain detailed MOA data from DrugBank API (DG002) to formally document COX-1/COX-2 inhibition profile
Review current international JIA treatment guidelines (ACR, EULAR, PRINTO) to position Diclofenac within the modern treatment algorithm, which now includes biologics and DMARDs
Conduct pediatric-specific safety assessment: GI tolerability, renal function monitoring, and cardiovascular risk in the pediatric age group
Clarify Philippines regulatory pathway: determine whether existing global pediatric use authorization (e.g., EU/US labeling) can support a local registration application
Evaluate whether the terminated SINCERE registry (NCT00688545) published safety data that can inform the Philippines context

⚠️ Research Use Only: The above findings are for drug repurposing research reference only and do not constitute medical advice. Repurposing candidates require clinical validation before application. All healthcare decisions must be made by qualified medical professionals in accordance with current clinical guidelines.

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.